HORIZON PHARMA, INC. FIRST AMENDMENT TO EXECUTIVE EMPLOYMENT AGREEMENTExecutive Employment Agreement • February 28th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • Illinois
This First Amendment to Executive Employment Agreement (this “Amendment”), amending that certain Executive Employment Agreement dated February 16, 2017 (the “Employment Agreement”), by and among Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation (hereinafter referred to together as the “Company”), and Michael DesJardin (the “Executive”), is entered into as of May 4, 2017 by and among the Company and the Executive. Capitalized terms used herein which are not defined herein shall have the definition ascribed to them in the Employment Agreement.
EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND MICHAEL DESJARDINEmployment Agreement • February 28th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • California
This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Road, Lake Forest, IL 60045 (hereinafter referred to together as the “Company”) and Michael DesJardin (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing February 16, 2017 (the “Effective Date”). Certain capitalized terms used in this Agreement have the meanings as set forth in Section 4.5.
EXECUTIVE EMPLOYMENT AGREEMENT BY AND BETWEEN HORIZON PHARMA, INC., HORIZON PHARMA USA, INC. AND SHAO-LEE LINExecutive Employment • February 28th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • Illinois
This Executive Employment Agreement (hereinafter referred to as the “Agreement”), is entered into by and between Horizon Pharma, Inc., a Delaware corporation, and its wholly owned subsidiary, Horizon Pharma USA, Inc., a Delaware corporation, each having a principal place of business at 150 S. Saunders Rd, Lake Forest IL 60045, (hereinafter referred to together as the “Company”) and Shao-Lee Lin (hereinafter referred as to the “Executive”). The terms of this Agreement shall be effective commencing January 4, 2018 (the “Effective Date”).
CONSULTING AGREEMENTConsulting Agreement • February 28th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations • Illinois
THIS CONSULTING AGREEMENT is made by and between Horizon Pharma USA, Inc. with its principal place of business at 150 South Saunders Road, Lake Forest, Illinois 60045 (“Company”), and DAVID HAPPEL, an individual residing at PO Box 203, 2362 Caballo Ranchero Drive, Diablo, CA 94528 (“Consultant”), effective February 1, 2018 (the “Effective Date”), for the purpose of setting forth the exclusive terms and conditions by which Company will acquire Consultant’s services on a limited and temporary basis. Company and Consultant may be referred to herein individually as a “Party,” or collectively as the “Parties.”
SECOND AMENDMENT TO THE SUPPLY AGREEMENT BETWEEN HORIZON PHARMA IRELAND LIMITED AND NUVO PHARMACEUTICALS INCSupply Agreement • February 28th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations
This AMENDMENT NO. 2 TO SUPPLY AGREEMENT (this “Amendment”) is made and entered into as of January 1, 2017 by and between Nuvo Pharmaceuticals .Inc., formerly known as Nuvo Research Inc., a company incorporated under the laws of the province of Ontario, Canada (“NUVO”), having offices at 7560 Airport Road, Unit 10, Mississauga, Ontario, L4T 4114, and Horizon Pharma Ireland Limited, a Irish limited company (“Horizon”), and amends that certain Supply Agreement, dated as of October 17, 2014, as amended by Amendment No. 1 to Supply Agreement, dated as of February 4, 2016 (the “Agreement”), by and between NUVO and Horizon. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Agreement.
THIRD AMENDMENT TO THE SUPPLY AGREEMENT BETWEEN HORIZON PHARMA IRELAND LIMITED AND NUVO PHARMACEUTICALS INCSupply Agreement • February 28th, 2018 • Horizon Pharma PLC • Pharmaceutical preparations
This AMENDMENT NO. 3 TO SUPPLY AGREEMENT (this “Amendment”) is made and entered into as of February 16, 2018 by and between Nuvo Pharmaceuticals Inc., formerly known as Nuvo Research Inc., a company incorporated under the laws of the province of Ontario, Canada (“NUVO”), having offices at 6733 Mississauga Road, Suite 610, Mississauga, ON L5N 6J5, Canada, and Horizon Pharma Ireland Limited, a Irish limited company (“Horizon Pharma”), and amends that certain Supply Agreement, dated as of October 17, 2014, as amended by Amendment No. 1 to Supply Agreement, dated as of February 4, 2016 and Amendment No. 2 to Supply Agreement, dated as of January 1, 2017 (collectively, the “Agreement”), by and between NUVO and Horizon Pharma. Capitalized terms used herein and not otherwise defined herein shall have the meanings assigned to such terms in the Agreement.
